Relationship Between Vedolizumab Concentrations and Deep Remission in Patients With Moderately-to-Severely Active Ulcerative Colitis: A GEMINI 1 Post Hoc Analysis

BACKGROUND: Deep remission is an important treatment goal for patients with ulcerative colitis (UC).1 Vedolizumab (VDZ), a gut-selective monoclonal antibody to α4β7 integrin, has demonstrated efficacy in achieving clinical remission in patients with UC.2 Here, we report a post hoc analysis of the phase 3 GEMINI 1 trial to determine if VDZ trough serum concentrations correlated with Week 52 deep remission rates in patients with UC. METHODS:...